Loading
A phase 1/2 trial of ProAgio Dose Levels (DL) 1,2,3,4 in triple-negative breast cancer, run by ProDa BioTech, LLC, now recruiting.
ProAgio in Combination With Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer is a phase 1/2 interventional study registered as NCT06460298 by ProDa BioTech, LLC, with 51 participants planned, started 2024-08-20 and due to reach its primary completion in 2027-07-01. Interventions recorded: ProAgio Dose Levels (DL) 1,2,3,4 and ProAgio Dose Expansion.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer (TNBC), Cytotoxic chemotherapy and the tag pipeline.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer (TNBC) and the tag pipeline.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer (TNBC), Cytotoxic chemotherapy and the tag pipeline.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer (TNBC) and the tag pipeline.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer (TNBC) and the tag pipeline.
Shares Gemcitabine, Cytotoxic chemotherapy and the tag pipeline.
Shares Gemcitabine, Cytotoxic chemotherapy and the tag pipeline.
Shares Gemcitabine, Cytotoxic chemotherapy and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/